Search results for "HEMATOPOIETIC STEM"

showing 10 items of 404 documents

A case of sjögren's syndrome with severe anemia due to myelitis

1986

An unusual case of Sjögren's syndrome presenting with severe anemia as the predominant clinical feature is described. Histological examination of a bone marrow biopsy specimen demonstrated that the patient's anemia was caused by myelitis and vasculitis of the small intraosseous vessels. Our report might stimulate a more thorough investigation of bone marrow in patients with connective tissue diseases and anemia.

MalePathologymedicine.medical_specialtyAnemiaConnective tissueMyelitisSevere anemiaBone Marrowhemic and lymphatic diseasesDrug DiscoveryBiopsymedicineHumansGenetics (clinical)medicine.diagnostic_testbusiness.industryAnemiaOsteomyelitisArteriesGeneral MedicineMiddle AgedHematopoietic Stem Cellsmedicine.diseasePolyarteritis NodosaSjogren's Syndromemedicine.anatomical_structureMolecular MedicineBone marrowSjogren sbusinessVasculitisKlinische Wochenschrift
researchProduct

Clinical manifestations and management of four children with Pearson syndrome.

2011

Pearson marrow-pancreas syndrome is a fatal disorder mostly diagnosed during infancy and caused by mutations of mitochondrial DNA. We hereby report on four children affected by Pearson syndrome with hematological disorders at onset. The disease was fatal to three of them and the fourth one, who received hematopoietic stem cell transplantation, died of secondary malignancy. In this latter patient transplantation corrected hematological and non-hematological issues like metabolic acidosis, and we therefore argue that it could be considered as a useful option in an early stage of the disease.

MalePediatricsmedicine.medical_specialtyMitochondrial DiseasesAnemiaMitochondrial diseasemedicine.medical_treatmenttrapianto cellule staminali emopoieticheHematopoietic stem cell transplantationDiseaseDNA MitochondrialLipid Metabolism Inborn Errorsmitochondrial disordersFatal OutcomeMuscular DiseasesCause of Deathhematopoietic stem cell transplantation; mitochondrial disorders; Pearson marrow-pancreas syndrome; trapianto cellule staminali emopoietiche; malattie mitocondriali; sindrome di PearsonGeneticsmedicineCongenital Bone Marrow Failure SyndromesHumansChildGenetics (clinical)Pearson marrow-pancreas syndromeCause of deathPearson syndromebusiness.industryAcyl-CoA Dehydrogenase Long-ChainHematopoietic Stem Cell TransplantationInfantMetabolic acidosissindrome di Pearsonmedicine.diseaseAnemia SideroblasticTransplantationChild PreschoolImmunologymalattie mitocondrialiFemalebusinessGene DeletionAmerican journal of medical genetics. Part A
researchProduct

Hematopoietic stem cell function in b-thalassemia is impaired and is rescued by targeting the bone marrow niche

2020

Abstract Hematopoietic stem cells (HSCs) are regulated by signals from the bone marrow (BM) niche that tune hematopoiesis at steady state and in hematologic disorders. To understand HSC-niche interactions in altered nonmalignant homeostasis, we selected β-thalassemia, a hemoglobin disorder, as a paradigm. In this severe congenital anemia, alterations secondary to the primary hemoglobin defect have a potential impact on HSC-niche cross talk. We report that HSCs in thalassemic mice (th3) have an impaired function, caused by the interaction with an altered BM niche. The HSC self-renewal defect is rescued after cell transplantation into a normal microenvironment, thus proving the active role of…

MaleStromal cellImmunologybone marrow mice thalassemia hematopoietic stem cells transplantation parathyroid hormoneSettore MED/08 - Anatomia PatologicaBiochemistryBone remodelingMiceBone MarrowmedicineAnimalsHumansOsteopontinStem Cell NicheHematopoietic stem cell β-thalassemia the bone marrow nichebiologybeta-ThalassemiaHematopoietic stem cellCell BiologyHematologyHematopoietic Stem CellsHematopoiesisMice Inbred C57BLTransplantationHaematopoiesismedicine.anatomical_structurebiology.proteinCancer researchFemaleBone marrowStem cell
researchProduct

Downregulation of β2-microglobulin in human cord blood somatic stem cells after transplantation into livers of SCID-mice: an escape mechanism of stem…

2002

Adherently growing, non-hematopoietic somatic stem cells isolated from human cord blood were stained with the fluorescent dye PKH26 and transplanted into livers of SCID-mice to examine a possible cell fate transition. Already 7 days after transplantation stem cells were well integrated into the liver tissue. Human albumin that was not expressed by the stem cells before transplantation was detectable in the host's livers after injection of cord blood stem cells. Human alpha1-antitrypsin was detectable in stem cells already before transplantation and remained positive in the mouse liver. The most interesting observation in this study was the downregulation of human beta2-microglobulin (beta2M…

MaleTranscriptional ActivationBiophysicsDown-RegulationMice SCIDBiologyBiochemistryMiceAlbuminsAnimalsHumansGene SilencingRNA MessengerMolecular BiologyAgedStem cell transplantation for articular cartilage repairInduced stem cellsStem CellsHematopoietic Stem Cell TransplantationAmniotic stem cellsCell BiologyFetal BloodImmunohistochemistryMolecular biologyEndothelial stem cellLiverAmniotic epithelial cellsCord bloodTransplantation ToleranceStem cellbeta 2-MicroglobulinStem Cell TransplantationAdult stem cellBiochemical and Biophysical Research Communications
researchProduct

Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absenc…

2011

Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection

MaleTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyPolymerase Chain ReactionAdenoviridaeAdenovirus Infections HumanTransplantationsurgical procedures operativeUnrelated DonorImmunologyHumansMedicineFemaleStem cellbusinessBone Marrow Transplantation
researchProduct

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation

2018

Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by…

Malebasic (laboratory) research/science0301 basic medicinemedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationGastroenterologyOrgan transplantation0302 clinical medicineRisk FactorsImmunology and AllergyPharmacology (medical)Whole bloodIncidenceHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedPrognosissurgical procedures operativeCytomegalovirus Infectionscytomegalovirus (CMV) [infection and infectious agents-viral]Femaleantiviral [antibiotic]pharmacokinetics/pharmacodynamicsImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtyinfectious diseasesirolimus [immunosuppressant-mechanistic target of rapamycin]clinical research/practicetacrolimus [immunosuppressant-calcineurin inhibitor]03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousTrough ConcentrationViremiabone marrow/hematopoietic stem cell transplantationAgedSirolimusTransplantationbusiness.industryTransplant RecipientsTacrolimus030104 developmental biologySpainRelative riskSirolimusDNA ViralpharmacologybusinessSerostatusFollow-Up Studies030215 immunology
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Feasibility of an exercise programme in elderly patients undergoing allogeneic stem cell transplantation - a pilot study

2015

It has been demonstrated that physical exercise benefits younger patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). We designed a prospective pilot study investigating whether elderly patients (>60 years) would also be able to participate in such a programme. It consisted of physiotherapist-supervised alternating endurance and resistance workouts on 6 of 7 days a week. Sixteen consecutive patients undergoing allo-HSCT were enrolled into the study. The median age was 64.5 years. Twelve patients participated in the programme until the time of discharge (75%) from the transplant unit. Therefore, the predefined criteria regarding feasibility were met. The reaso…

Malemedicine.medical_specialtyPopulationPilot ProjectsPhysical exercise03 medical and health sciences0302 clinical medicineQuality of lifeEndurance trainingHumansTransplantation HomologousMedicineMuscle StrengthProspective StudiesMuscle SkeletalAdverse effecteducationAgededucation.field_of_studybusiness.industryHematopoietic Stem Cell TransplantationMiddle AgedExercise TherapyExercise programmeTransplantationOncologyHematologic Neoplasms030220 oncology & carcinogenesisQuality of LifePhysical therapyFeasibility StudiesPatient ComplianceFemaleStem cellbusiness030215 immunologyEuropean Journal of Cancer Care
researchProduct

Characterization of a T-cell-derived mast cell costimulatory activity (MCA) that acts synergistically with interleukin 3 and interleukin 4 on the gro…

1990

The proliferation of mucosal mast cells (MMC) depends on the presence of interleukin 3 (IL 3) and can be further enhanced by interleukin 4 (IL 4). The supernatant of a TH2 cell clone (ST2/K.9) stimulated by concanavalin A was found to contain a factor, provisionally termed mast cell costimulatory activity (MCA), that substantially enhances the proliferation of MMC promoted by a combination of IL 3 and IL 4. In comparison to other lymphokines MCA is rather resistant to tryptic digestion but is very sensitive to pH values lower than 6.0 and to organic solvents. Chromatographic fractionation of MCA revealed that activity is associated with protein(s) or glycoprotein(s) of 35 to 40 kDa. Partial…

Malemedicine.medical_specialtyT-LymphocytesImmunologyBone Marrow CellsBiologyBiochemistryMast cell proliferationCell LineBiological FactorsMiceEpidermal growth factorInternal medicinemedicineImmunology and AllergyAnimalsMast CellsMolecular BiologyInterleukin 4Interleukin 3LymphokinesLymphokineDrug SynergismHematologyMast cellHematopoietic Stem CellsMolecular biologyClone Cellsmedicine.anatomical_structureEndocrinologyMice Inbred DBAChromatography GelCytokinesTumor necrosis factor alphaFemaleInterleukin-3Interleukin-4Leukemia inhibitory factorCell DivisionCytokine
researchProduct

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent…

2015

Summary Background Acute myeloid leukaemia mainly affects elderly people, with a median age at diagnosis of around 70 years. Although about 50–60% of patients enter first complete remission upon intensive induction chemotherapy, relapse remains high and overall outcomes are disappointing. Therefore, effective post-remission therapy is urgently needed. Although often no post-remission therapy is given to elderly patients, it might include chemotherapy or allogeneic haemopoietic stem cell transplantation (HSCT) following reduced-intensity conditioning. We aimed to assess the comparative value of allogeneic HSCT with other approaches, including no post-remission therapy, in patients with acute…

Malemedicine.medical_specialtyTransplantation ConditioningGemtuzumab ozogamicinmedicine.medical_treatmentAntibodies Monoclonal HumanizedCOUNCIL AML11 TRIALEUROPEAN LEUKEMIANETInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointINDUCTION CHEMOTHERAPYHumansTransplantation HomologousProspective StudiesADULT PATIENTS610 Medicine & healthBusulfanMETAANALYSISAgedMYELODYSPLASTIC SYNDROMEChemotherapyRISK-ADAPTED APPROACHbusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInduction chemotherapyHematology1ST COMPLETE REMISSIONTotal body irradiationMiddle AgedGemtuzumabGEMTUZUMAB OZOGAMICINSurgeryFludarabineTransplantationSurvival RateLeukemia Myeloid AcuteAminoglycosidesTreatment OutcomeSURVIVALFemaleNeoplasm Recurrence LocalbusinessBusulfanVidarabinemedicine.drugLancet. Haematology
researchProduct